



Clinical Network Services (CNS) UK Announces the Appointment of Dr Martin Moxham as Principal Regulatory Consultant

Brisbane, Australia - 3 January 2017 - Clinical Network Services (CNS), an integrated service group focused on clinical product development and headquartered in Australia with offices in New Zealand, the UK and the USA, has announced the appointment of Martin Moxham as Principal Regulatory Consultant for Europe from 1 January 2017.

With over 24 years industry experience, Martin is a highly respected pharmaceutical regulatory affairs specialist with particular expertise in EU regulatory strategy, clinical and nonclinical data evaluation and supporting scientific advice meetings.

Commenting on the new role, Martin said: "I am delighted to join the CNS' BioDesk UK consulting team, as this is an exciting opportunity to work within a highly professional and experienced group that is dedicated to adding value to client programs. "

Russell Neal, Managing Director said: "Martin brings a wealth of industry and consulting experience to our UK BioDesk team and reflects CNS' ongoing commitment to the continuous growth and evolution of BioDesk servicing the breadth of CNS' international clients"

CNS' BioDesk division is an intelligent global product development and regulatory affairs consultancy specialising in readying products to swiftly enter the clinic or gain marketing approval. With an average of over 13 years per consultant, BioDesk offers clients one of the most experienced and integrated groups of regulatory, CMC/manufacturing, toxicological, clinical and medical expert teams available across three continents.

CNS has experience on almost 500 distinct early phase projects across over 120 indications with particular expertise provided by BioDesk in the areas of vaccines, infectious disease products, cell and gene therapies.

- ends -

Contact:

Clinical Network Services	Instinctif Partners
Russell Neal T: +61 (0)7 3719 6000 russell.neal[at]clinical.net.au	Sue Charles/Dr Christelle Kerouedan/Rosanna Forest T: +44 (0)20 7457 2020 CNS[at]instinctif.com

About Clinical Network Services

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA, who create value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS' regional clinical advantage is driven by

the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.

CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables CNS to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.

Further information about CNS and its intelligent development services can be found at www.clinical.net.au

About BioDesk:

CNS' BioDesk is an expert consulting team offering CMC/manufacturing, toxicology, clinical and regulatory affairs consulting services for readying products to enter clinical trials or marketing approval.

The BioDesk team consists of experienced chemists, toxicologists, medical writers, regulatory affairs specialists and experienced clinicians based in Australia, Europe and the USA. BioDesk works closely with clients to design and implement manufacturing operations and non-clinical plans, mindful of commercial timelines and budgets. BioDesk further adds value by ensuring that a global regulatory standard is inherent within client development programs. After submission of a marketing approval, BioDesk collaboratively works with the experienced Australian/New Zealand clinical operations and biometrics teams to realise client goals.

BioDesk core services include:

- Developing clinical development plans and drug development plans - starting with the end in mind.
- Getting client GMP-compliant clinical trial material ready for the clinic.
- Arranging meetings with international regulators and helping clients ask optimal questions in order to elicit helpful responses.
- Writing up all applications for the regulators including big or small projects: orphan applications, paediatric investigational plans, to New Drug Applications and everything in between.
- Providing medical writers to write up protocols, investigator brochures and all modules in the Common Technical Dossier required for a marketing application.

Further information about BioDesk services can be found at www.cnsbiodesk.com